| Trial ID: | L0660 |
| Source ID: | NCT00117104
|
| Associated Drug: |
Aranesp®
|
| Title: |
Evaluating Aranesp® in Subjects With End Stage Renal Disease onChronic Hemodialysis
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
End Stage Renal Disease
|
| Interventions: |
DRUG: Aranesp®
|
| Outcome Measures: |
Primary: Target hemoglobin (Hgb) | Secondary: Distribution of hemoglobin (Hgb) values by week
|
| Sponsor/Collaborators: |
Sponsor: Amgen
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
|
| Completion Date: |
|
| Results First Posted: |
|
| Last Update Posted: |
2009-10-16
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT00117104
|
